식물 유래 고리형 펩티드 시장 예측(2026-2032년)

The Plant-derived Cyclic Peptide Market is projected to grow by USD 397.89 million at a CAGR of 10.44% by 2032.

Plant-Derived Cyclic Peptides: Executive Overview

Plant-derived cyclic peptides are bioactive molecules produced by plants and investigated for their structural stability, target specificity, and potential applications in pharmaceutical discovery, agriculture, and biotechnology. Interest is shaped by advances in peptide isolation, sequencing, synthetic biology, and analytical characterization. The field remains research-intensive, with translation dependent on reproducible sourcing, validated biological activity, safety assessment, and scalable manufacturing.

From Natural Discovery to Engineered Peptide Platforms

The landscape is shifting from traditional extraction toward integrated discovery platforms that combine genomics, transcriptomics, mass spectrometry, structural biology, and computational screening. Researchers are increasingly prioritizing standardized workflows, sequence-to-function mapping, and engineered production systems to address variability in plant material and limitations in purification. Regulatory expectations, intellectual-property considerations, biodiversity stewardship, and sustainable cultivation are also becoming central to commercialization strategies.

Artificial Intelligence Accelerates Discovery and Development

Artificial intelligence can improve the identification and prioritization of plant-derived cyclic peptides by analyzing sequence patterns, precursor genes, structural features, and biological assay results. Machine learning may support activity prediction, toxicity screening, de novo design, and optimization of production conditions, while natural-language processing can help organize dispersed scientific literature. Its value depends on high-quality experimental datasets, transparent validation, careful handling of biological uncertainty, and confirmation through laboratory testing rather than computational predictions alone.

Regional Insights Across Research and Manufacturing Ecosystems

North America combines advanced peptide science, biotechnology infrastructure, and translational research capabilities, while Latin America offers important plant biodiversity and opportunities for responsible bioprospecting. Europe emphasizes rigorous characterization, sustainability, and coordinated research frameworks. The Middle East is developing life-science capacity and may benefit from controlled-environment cultivation, whereas Africa presents substantial biodiversity alongside infrastructure, conservation, and technology-transfer priorities. Asia-Pacific brings extensive traditional botanical knowledge, expanding biopharmaceutical capabilities, and strong activity in genomics, natural-products research, and process development.

Group Insights: Cooperation, Regulation, and Supply-Chain Alignment

ASEAN countries can strengthen discovery through biodiversity cooperation, shared analytical capacity, and harmonized access-and-benefit-sharing practices. BRICS economies offer complementary strengths in plant resources, research institutions, manufacturing, and domestic healthcare priorities. The European Union supports coordinated scientific and regulatory approaches, while the G7 contributes advanced discovery, data, and translational capabilities. GCC members can support investment, controlled cultivation, and biotechnology infrastructure, and NATO members may benefit from collaboration in biosecurity, resilient supply chains, and advanced life-science research while maintaining civilian research safeguards.

Country-Level Priorities in Plant-Derived Cyclic Peptides

Australia can leverage distinctive biodiversity and strong bioscience governance; Brazil combines exceptional botanical resources with major opportunities in sustainable discovery. Canada offers advanced research and analytical capacity, while China and India provide extensive natural-products expertise, manufacturing depth, and large scientific talent pools. France, Germany, Italy, Spain, and the United Kingdom contribute strong capabilities in chemistry, pharmacology, biotechnology, and regulatory science. Japan and South Korea bring sophisticated analytical, pharmaceutical, and fermentation technologies. Mexico can connect biodiversity-based research with regional manufacturing and clinical capabilities. Russia has relevant scientific and botanical resources, although collaboration may be affected by regulatory, logistical, and institutional constraints. The United States remains a major center for translational research, advanced instrumentation, and biotechnology development.

Priorities for Leaders: Validate Biology, Secure Supply, and Scale Responsibly

Industry leaders should establish end-to-end programs linking biodiversity assessment, sequence discovery, functional screening, and standardized analytical confirmation. Partnerships with botanical institutions, universities, contract laboratories, and manufacturing specialists can reduce capability gaps while improving reproducibility. Organizations should build traceable sourcing and access-and-benefit-sharing controls, protect sequence and process know-how appropriately, and use staged development gates tied to potency, selectivity, stability, safety, and manufacturability. AI initiatives should be paired with curated datasets and prospective experimental validation. Early dialogue with regulators and investment in scalable, environmentally responsible production can reduce later development risk.

Methodology: Evidence-Based Synthesis of the Emerging Field

This executive summary uses the defined market scope of plant-derived cyclic peptides and organizes findings across technology, application, geography, economic grouping, and country-level considerations. The assessment emphasizes publicly verifiable scientific and institutional evidence, including peer-reviewed research, technical publications, regulatory materials, biodiversity frameworks, and documented biotechnology practices. Qualitative conclusions are based on recurring evidence regarding discovery methods, analytical capabilities, manufacturing constraints, sustainability, and translational requirements. No market estimates, shares, forecasts, or unverified company-specific claims are used.

Conclusion: Build a Traceable and Data-Driven Development Model

Plant-derived cyclic peptides offer a promising interface between natural-product science, peptide engineering, and biotechnology. Progress will depend less on discovery volume alone than on reliable sequence assignment, biological validation, sustainable access to plant resources, and reproducible production. Regions and country groups with complementary capabilities can accelerate advancement through shared infrastructure, harmonized governance, and responsible data collaboration. Leaders that combine AI-assisted prioritization with rigorous laboratory evidence and scalable manufacturing will be best positioned to convert scientific potential into credible applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Plant-derived Cyclic Peptide Market, by Product Type

• 7.1. Introduction
• 7.2. Cyclic Dipeptides
• 7.3. Cyclotides
• 7.4. Lipopeptides

8. Plant-derived Cyclic Peptide Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intramuscular
  • 8.2.2. Intravenous
  • 8.2.3. Subcutaneous
• 8.3. Oral
  • 8.3.1. Capsule
  • 8.3.2. Tablet
• 8.4. Topical
  • 8.4.1. Cream
  • 8.4.2. Gel

9. Plant-derived Cyclic Peptide Market, by Manufacturing Process

• 9.1. Introduction
• 9.2. Enzymatic Synthesis
• 9.3. Liquid Phase Peptide Synthesis
• 9.4. Recombinant Biosynthesis
• 9.5. Solid Phase Peptide Synthesis
  • 9.5.1. Boc Chemistry
  • 9.5.2. Fmoc Chemistry

10. Plant-derived Cyclic Peptide Market, by Molecular Weight

• 10.1. Introduction
• 10.2. Less Than 1 KDa
• 10.3. 1 To 5 KDa
• 10.4. Greater Than 5 KDa

11. Plant-derived Cyclic Peptide Market, by Application

• 11.1. Introduction
• 11.2. Anticancer
  • 11.2.1. Breast Cancer
  • 11.2.2. Lung Cancer
• 11.3. Antimicrobial
  • 11.3.1. Antibacterial
  • 11.3.2. Antifungal
• 11.4. Antiviral
  • 11.4.1. Hepatitis
  • 11.4.2. HIV
  • 11.4.3. Influenza
• 11.5. Immunosuppressive
  • 11.5.1. Autoimmune Disorders
  • 11.5.2. Organ Transplantation

12. Plant-derived Cyclic Peptide Market, by End User

• 12.1. Introduction
• 12.2. Academic Research Institutes
• 12.3. Biotechnology Companies
• 12.4. Contract Research Organizations
• 12.5. Pharmaceutical Companies

13. Plant-derived Cyclic Peptide Market, by Region

• 13.1. Introduction
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Europe
• 13.6. Middle East
• 13.7. Africa

14. Plant-derived Cyclic Peptide Market, by Group

• 14.1. Introduction
• 14.2. ASEAN
• 14.3. GCC
• 14.4. European Union
• 14.5. BRICS
• 14.6. G7
• 14.7. NATO

15. Plant-derived Cyclic Peptide Market, by Country

• 15.1. Introduction
• 15.2. United States
• 15.3. Canada
• 15.4. Mexico
• 15.5. Brazil
• 15.6. United Kingdom
• 15.7. Germany
• 15.8. France
• 15.9. Russia
• 15.10. Italy
• 15.11. Spain
• 15.12. China
• 15.13. India
• 15.14. Japan
• 15.15. Australia
• 15.16. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. Market Concentration Analysis, 2025
  • 16.2.1. Concentration Ratio (CR)
  • 16.2.2. Herfindahl Hirschman Index (HHI)
• 16.3. Recent Developments & Impact Analysis, 2025
• 16.4. Product Portfolio Analysis, 2025
• 16.5. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abzena Limited
• 17.2. AmbioPharm, Inc.
• 17.3. AstraZeneca PLC
• 17.4. Bachem Holding AG
• 17.5. Biosynth Ltd.
• 17.6. Corden Pharma International GmbH
• 17.7. Creative Peptides, Inc.
• 17.8. Eli Lilly and Company
• 17.9. GenScript Biotech Corporation
• 17.10. JPT Peptide Technologies GmbH
• 17.11. Kaneka Corporation
• 17.12. Lonza Group AG
• 17.13. Merck KGaA
• 17.14. Novartis AG
• 17.15. Peptide Therapeutics Ltd.
• 17.16. PeptiDream Inc.
• 17.17. Pfizer Inc.
• 17.18. PolyPeptide Group AG
• 17.19. Thermo Fisher Scientific Inc.
• 17.20. WuXi AppTec Co., Ltd.

18. Key Experts